RxDoctor Payments Data

Genevieve Corbett

Nurse Practitioner · Anchorage, AKNPI 1851773469

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,943 of the $3,156 with a category attached, or 61.6%. 6 manufacturers reported payments, led by Boston Scientific at 48.1% of the total. Reporting peaked in 2024 at $1,426 and has fallen 84.7% since, to $218 in 2025. Among nurse practitioner clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,156in general payments, 2019–2025

Across 33 payments — averaging $95.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Avadel CNS Pharmaceuticals, LLC$57
  • Amneal Pharmaceuticals LLC$47
  • TG Therapeutics, Inc.$28
  • Neurocrine Biosciences, Inc.$13

What the payments were for

  • Travel & lodging$1,94362%
  • Food & beverage$1,16837%
  • Education$451%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,156 in reported general payments places this provider in the 95th percentile of 212 nurse practitioner providers in Alaska.

See all nurse practitioner providers in Alaska

Medicare billing

Part B allowed, 2024
$121,101
Medicare patients
565
Services billed
1,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa43$53,595
Carbidopa-LevodopaCarbidopa/Levodopa260$13,807
OngentysOpicapone12$8,631
Pramipexole ErPramipexole Di-Hcl11$5,790
Carbidopa-Levodopa ErCarbidopa/Levodopa91$5,426
Ropinirole ErRopinirole Hcl23$3,003
Propranolol Hcl28$1,351
AmantadineAmantadine Hcl17$1,151
Propranolol Hcl ErPropranolol Hcl14$1,142
RivastigmineRivastigmine Tartrate19$1,077
Primidone26$1,072
Modafinil15$758
Donepezil Hcl42$652
Pramipexole DihydrochloridePramipexole Di-Hcl38$461
Gabapentin32$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$47$53,59543 claims
Neurocrine Biosciences, Inc.Ongentys$13$8,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 212 nurse practitioner providers in Alaska.

Other nurse practitioner in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →